Advertisement

Migräne pp 379-389 | Cite as

Überblick zur Rolle der 5-HT3-Rezeptorantagonisten in der Migränetherapie

  • Michel Dominique Ferrari
  • Franz Bernhard M. Ensink

Zusammenfassung

Wie bereits in Kap. 13 ausführlich dargestellt, spielt 5-Hydroxytryptamin vermutlich eine entscheidende Rolle bei der Pathophysiologie der Migräne [27, 31]. Infolge der Entdeckung sogenannter 5-HT3-Rezeptoren (vgl. 2.5.3.4), einer speziellen Untergmppe innerhalb des serotoninergen Systems (vgl. Kap. 12), wurde die Hypothese aufgestellt, daß eine Aktivierung dieser Rezeptorstmkturen eine Kettenreaktion induziert, die letztendlich zu den typischen Migränebeschwerden führen könnte. Vor diesem Hintergrund wurden bislang 4 selekdve 5-HT3-Rezeptorantagonisten zur symptomatischen und prophylaktischen Migränetherapie untersucht. In diesem Beitrag sollen die folgenden 4 Punkte abgehandelt werden:
  1. 1.

    Darstellung der Pharmakologie der 5-HT3-Rezeptoren, soweit sie für das Verständnis der Pathogenese der Migräne von Bedeutung ist;

     
  2. 2.

    Erörtemng des gedanklichen Konzepts, durch Blockade von 5-HT3-Rezeptoren das Migränegeschehen therapeudsch beeinflussen zu wollen;

     
  3. 3.

    Präsentation und kridsche Würdigung der in der Migränetherapie mit 5-HT3-Rezeptorantagonisten erzielten klinischen Resultate;

     
  4. 4.

    Diskussion des zukünftigen Stellenwerts der 5-HT3-Rezeptorantagonisten für die Migränetherapie.

     

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Anthony M (1986) The biochemistry of migraine. In: Vinken PJ, Bmyn GW, Klawans HL, Clifford Rose F (eds) Headache. (Handbook of clinical neurology, vol 4 [48]). Elsevier Science, Amsterdam New York, pp 85–105Google Scholar
  2. 2.
    Bradley PB, Engel G, Feniuk W, Fozard JR, Humphrey PPA, Middlemiss DN, Mylecharane EJ, Richardson BP, Saxena PR (1986) Proposals for the classification and nomenclature of functional receptors for 5-hydroxytryptamine. Neuropharmacology 25: 563–576PubMedCrossRefGoogle Scholar
  3. 3.
    Butler A, Hill JM, Ireland SJ, Jordan CC, Tyers MB (1988) Pharmacological properties of GR38032F, a novel antagonist at 5-HT3 receptors. Br J Pharmacol 94: 397–412PubMedGoogle Scholar
  4. 4.
    Couturier EGM, Hering R, Foster CA, Steiner TJ, Clifford Rose F (1991) First clinical study of the selective 5-HT3 antagonist, granisetron (BRL 43694), in the acute treatment of migraine headache. Headache 31: 296–297PubMedCrossRefGoogle Scholar
  5. 5.
    Cubeddu LX, Hoffmann IS, Fuenmayor NT, Finn AL (1990) Efficacy of ondansetron (GR 38032F) and the role of serotonin in cisplatin-induced nausea and vomiting. N Engl J Med 322: 810–816PubMedCrossRefGoogle Scholar
  6. 6.
    Dahlöf C, Winter P, Ludlow S (1989) Oral GR43175, a 5-HT1-like agonist, for treatment of the acute migraine attack: an intemational study - preliminary results. Cephalalgia 9 [Suppl 10]: 351–352Google Scholar
  7. 7.
    Edvinsson L, Degueurce A, Duverger D, MacKenzie ET, Scatton B (1983) Central serotonergic nerves project to the pial vessels of the brain. Nature 306: 55–57PubMedCrossRefGoogle Scholar
  8. 8.
    Ferrari MD (1991) 5-HT3 receptor antagonists and migraine therapy. J Neurol 238 [Suppl 1]: S53-S56PubMedCrossRefGoogle Scholar
  9. 9.
    Ferrari M, Bayliss EM, Ludlow S, Pilgrim AJ (1989) Subcutaneous GR43175 in the treatment of acute migraine: an intemational study. Cephalalgia 9 [Suppl 10]: 348Google Scholar
  10. 10.
    Ferrari MD, Odink J, Tapparelli C, Kempen GMJ van, Pennings EJM, Bruyn GW (1989) Serotonin metabolism in migraine. Neurology 39: 1239–1242PubMedGoogle Scholar
  11. 11.
    Ferrari MD, Wilkinson M, Hirt D, Lataste X, Notter M [and the ICS 205–930 migraine study group] (1991) Efficacy of ICS 205–930, a novel 5-hydroxytryptamines (5-HT3) receptor antagonist, in the prevendon of migraine attacks. A complex answer to a simple question. Pain 45: 283–291Google Scholar
  12. 12.
    Fitzgerald M (1989) Arthrhis and the nervous system. Trends Pharmacol Sci 12: 86–87Google Scholar
  13. 13.
    Fozard JR (1982) Basic mechanism of antimigraine drugs. Adv Neurol 33: 295–307PubMedGoogle Scholar
  14. 14.
    Fozard JR (1984) MDL 72222: a potent and highly selective antagonist at neuronal 5-hydroxytryptamine receptors. Naunyn Schmiedebergs Arch Pharmacol 326: 36–44PubMedCrossRefGoogle Scholar
  15. 15.
    Fozard JR (1984) Neuronal 5-HT receptors in the periphery. Neuropharmacology 23: 1473–1486PubMedCrossRefGoogle Scholar
  16. 16.
    Fozard JR (1990) Agonists and antagonists of 5-HT3 receptors. In: Saxena PR, Wallis DI, Wouters W, Bevan P (eds) Cardiovascular pharmacology of 5-hydroxy tryptamine: prospective therapeutic applications. Kluwer, Dordrecht Boston, pp 101–115Google Scholar
  17. 17.
    Fozard JR (1990) 5-HT3 receptors. In: Paoletti R, Vanhoutte PM, Brunello N, Maggi FM (eds) Serotonin: from cell biology to pharmacology and therapeudcs. Kluwer, Dordrecht Boston, pp 331–338Google Scholar
  18. 18.
    Fozard JR, Mobarok Ali ATM (1978) Blockade of neuronal tryptamine receptors by metoclopramide. Eur J Pharmacol 49: 109–112PubMedCrossRefGoogle Scholar
  19. 19.
    Fozard JR, Mobarok Ali ATM, Newgrosh G (1979) Blockade of serotonin receptors on autonomic neurones by (-)-cocaine and some related compounds. Eur J Pharmacol 59: 195–210PubMedCrossRefGoogle Scholar
  20. 20.
    Gaddum JH, Picarelli ZP (1957) Two kinds of tryptamine receptor. Br J Pharmacol 12: 323–328Google Scholar
  21. 21.
    Giordano J, Dyche J (1989) Differendal analgesic actions of serotonin 5-HT3 receptor antagonists in the mouse. Neuropharmacology 28: 423–427PubMedCrossRefGoogle Scholar
  22. 22.
    Giordano J, Rogers LV (1989) Peripherally administered serotonin 5-HT3 receptor antagonists reduce inflammatory pain in rats. Eur J Pharmacol 170: 83–86PubMedCrossRefGoogle Scholar
  23. 23.
    Glaum SR, Anderson EG (1988) Identificadon of 5-HT3 binding sites in rat spinal cord synaptosomal membranes. Eur J Pharmacol 156: 287–290PubMedCrossRefGoogle Scholar
  24. 24.
    Gralla RJ, Kris MG, Clark RA, Tyson LB (1988) Random-assignment antiemetic trial of different dosage schedules of the serotonin antagonist GR-C507/75 (38032F) in patients receiving high dose cisplatin. Proc Am Soc Clin Oncol 7: 296Google Scholar
  25. 25.
    Griffith SG, Burnstock G (1983) Immunohistochemical demonstration of serotonin in nerves supplying human cerebral and mesenteric blood-vessels. Lancet 1: 561–562PubMedCrossRefGoogle Scholar
  26. 26.
    Hughes JB (1977) Metoclopramide in migraine treatment. Med J Aust 2: 580PubMedGoogle Scholar
  27. 27.
    Humphrey PPA (1991) 5-Hydroxytryptamine and the pathophysiology of migraine. J Neurol 238 [Suppl 1]: S38-S44PubMedCrossRefGoogle Scholar
  28. 28.
    Kilpatrick GJ, Jones BJ, Tyers MB (1987) Identification and distribution of 5-HT3 receptors in rat brain using radioligand binding. Nature 330: 746–748PubMedCrossRefGoogle Scholar
  29. 29.
    Kilpatrick GJ, Jones BJ, Tyers MB (1990) Brain 5-HT3 receptors. In: Paoletti R, Vanhoutte PM, Brunello N, Maggi FM (eds) Serotonin: from cell biology to pharmacology and therapeutics. Kluwer, Dordrecht Boston, pp 339–345Google Scholar
  30. 30.
    King FD, Sanger GJ (1989) 5-HT3 receptor antagonists. Drugs Future 14: 875–889Google Scholar
  31. 31.
    Lance JW, Lambert GA, Goadsby PJ, Zagami AS (1989) 5-Hydroxy try ptamine and its putative aetiological involvement in migraine. Cephalalgia 9 [Suppl 9]: 7–13PubMedGoogle Scholar
  32. 32.
    Lataste X, Ferrari MD, Hirt D, Notter M, Wilkinson M (1989) Efficacy and to-lerability of ICS 205–930, a 5-HT3 receptor antagonist in migraine prophylaxis. Cephalalgia 9 [Suppl 10]: 346–347Google Scholar
  33. 33.
    Loisy C, Beorchia S, Centonze V, Fozard JR, Schlechter PJ, Tell GP (1985) Effects on migraine headache of MDL 72222, an antagonist at neuronal 5-HT receptors. Double-blind, placebo controlled study. Cephalalgia 5: 79–82PubMedCrossRefGoogle Scholar
  34. 34.
    Moskowitz MA, Buzzi MG (1991) Neuroeffector functions of sensory fibres: implications for headache mechanisms and drug actions. J Neurol 238 [Suppl 1]: S18-S22PubMedCrossRefGoogle Scholar
  35. 35.
    Moskowitz MA, Henrikson BM, Markowitz S, Saito K (1988) In: Olesen J, Edvinsson L (eds) Basic mechanisms of headache. Elsevier, Amsterdam New York, pp 429–437Google Scholar
  36. 36.
    Moss HE, Sanger GJ (1987) Antagonism by BRL 43694 of the pseudoaffective reflex induced by duodenal distension. Br J Pharmacol 92: 53IPGoogle Scholar
  37. 37.
    Nieuwenhuys R (1985) Chemoarchitecture of the brain. Springer, Berlin Heidelberg New York Tokyo, S 33–41CrossRefGoogle Scholar
  38. 38.
    Patten JP [For the oral sumatriptan dose-defining study group] (1991) Clinical experience with oral sumatriptan: a placebo-controlled, dose-ranging study. J Neurol 238 [Suppl 1]: S62-S65CrossRefGoogle Scholar
  39. 39.
    Pratt GD, Bowery NG, Kilpatrick GJ et al. (1990) Consensus meeting agrees distribution of 5-HT3 receptors in mammalian hindbrain. Trends Pharmacol Sci 11: 135–137PubMedCrossRefGoogle Scholar
  40. 40.
    Richardson BP, Engel G (1986) The pharmacology and function of 5-HT3 receptors. Trends Neurosci 9: 424–428CrossRefGoogle Scholar
  41. 41.
    Richardson BP, Engel G, Donatsch P, Stadler PA (1985) Identification of serotonin M-receptor subtypes and their specific blockade by a new class of drugs. Nature 316: 126–131PubMedCrossRefGoogle Scholar
  42. 42.
    Rowat BMT, Merrill CF, Davis A, South V (1991) A double-blind comparison of granisetron and placebo for the treatment of acute migraine in the emergency department Cephalalgia 11: 207–213Google Scholar
  43. 43.
    Sanger GJ (1987) Increased gut cholinergic activity and antagonism of 5-hydroxytryptamine M-receptors by BRL 24924: potential clinical importance of BRL 24924. Br J Pharmacol 91: 77–87PubMedGoogle Scholar
  44. 44.
    Saxena PR, Ferrari MD (1989) 5-HT1-like receptor agonists the pathophysiology of migraine. Trends Pharmacol Sci 10: 200–204PubMedCrossRefGoogle Scholar
  45. 45.
    Scatton B, Duverger D, L’Heureux R, Serrano A, Fage D, Nowicki JP, MacKenzie ET (1985) Neurochemical studies in the existence, origin and characteristics of the serotoninergic innervation of small piai vessels. Brain Res 345: 219–229PubMedCrossRefGoogle Scholar
  46. 46.
    Sicuteri F, Fanciullacci M, Franchi G, Del Bianco PL (1965) Serotonin-bradykinin potentiation on the pain receptors in man. Life Sci 4: 309–316PubMedCrossRefGoogle Scholar
  47. 47.
    Smith WW, Sancilio LF, Owera-Atepo JB, Naylor RJ, Lambert L (1988) Zacopride, a potent 5-HT3 antagonist. J Pharm Pharmacol 40: 301–302CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1994

Authors and Affiliations

  • Michel Dominique Ferrari
  • Franz Bernhard M. Ensink

There are no affiliations available

Personalised recommendations